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Introduction
Major structural birth defects collectively affect 3 to 5% of births in the United States and 
contribute substantially to mortality and morbidity (CDC, 2008; TDSHS, 2015). Since 2000, 
the National Birth Defects Prevention Network (NBDPN) has annually published state-
specific data for selected major birth defects affecting a range of organ systems, including 
central nervous, eye, ear, cardiovascular, orofacial, gastrointestinal, genitourinary, and 
musculoskeletal, as well as chromosomal and other conditions, such as amniotic bands. 
*Correspondence to: Cara T. Mai, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and 
Prevention, 4770 Buford Highway, MS E-86, Atlanta, GA 30341. cmai@cdc.gov. 
Additional Supporting Information may be found in the online version of this article.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
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While the NBPDN list of birth defects had remained relatively unchanged for two decades, 
it was recently revised and released with the 2014 NBDPN Annual Report (Mai et al., 
2014). Several factors necessitated an in-depth examination of the list of conditions: (1) 
development of national data quality standards for birth defects surveillance in the United 
States; (2) transition of the diagnostic coding system from the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) to ICD-10-CM; and (3) inclusion 
of newborn screening for critical congenital heart defects (CCHD), with 12 primary and 
secondary CCHD targets, on the national Recommended Uniform Screening Panel. The 
revision process included a review of each condition in relation to its public health 
importance, state of current knowledge, and clinical factors, such as accuracy of diagnosis 
within a child’s first year of life. Table 1 presents the revised list of birth defects and their 
diagnostic codes [ICD-9-CM and Centers for Disease Control and Prevention/British 
Pediatric Association Classification of Diseases (CDC/BPA)].
The data component of the 2015 NBDPN Annual Report comprises: (1) state-specific data 
from 41 population-based birth defects surveillance programs for the 47 major birth defects 
listed in Table 1; (2) a directory of state birth defects surveillance programs, which details 
data collection, surveillance methodology, and birth defects contacts; and (3) a descriptive 
data brief further highlighting the variability in prevalence estimates across population-
based birth defects programs.
State-Specific Data Collection and Presentation of 47 Major Birth Defects
Starting in February 2015, the NBDPN Data Committee, in collaboration with CDC, 
reviewed and refined the data collection process. This included updating the data dictionary 
and determining the focus of the data brief. A call for data was then issued in April 2015 to 
population-based birth defects surveillance programs in the United States. Programs were 
asked to submit data using templates provided in Excel or SAS (SAS Institute, Inc., Cary, 
NC). CDC performed data quality checks, and state programs validated their data and 
approved final data table presentation.
Participating birth defects surveillance programs submitted case counts of the reportable 
birth defects shown in Table 1 and the number of live births occurring from January 1, 2008 
through December 31, 2012. These cases were stratified by U.S. Census maternal racial/
ethnic groups: non-Hispanic white, non-Hispanic black, Hispanic, non-Hispanic Asian/
Pacific Islander, non-Hispanic American Indian/Alaska Native, and other/unknown. 
Additionally, as maternal age is strongly associated with selected trisomies and 
gastroschisis, case counts for these defects were submitted stratified by maternal age at 
delivery in six categories: less than 20 years, 20 to 24 years, 25 to 29 years, 30 to 34 years, 
35 to 39 years, and 40 + years.
STATE-SPECIFIC DATA PRESENTATION
State-specific data from 41 population-based birth defects surveillance programs for 2008 to 
2012 are shown electronically at Supporting Information. The data are presented in two 
tables for each state program. The first table shows birth defect counts and prevalence per 
10,000 live births by maternal racial/ethnic categories. The second table presents counts and 
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prevalence for trisomies and gastroschisis by two maternal age categories (less than 35 
years, 35 + years). The prevalence is calculated by dividing the number of birth defect cases 
for any pregnancy outcome by the total number of live births for the reported years and then 
multiplying by 10,000 (Mason et al., 2005). The denominator used to calculate the 
prevalence for all birth defects is total live births except for hypospadias and Turner 
syndrome, which are calculated using total male live births and total female live births, 
respectively.
State-specific notes and clarifications about the data, such as methodologic changes and 
inclusion of probable/possible diagnoses, are included in the data tables. Additional 
information about each state program methodology is available in the accompanying birth 
defects program directory.
Descriptive Data Brief on Observed Variability in Prevalence Estimates 
Across Population-Based Birth Defects Programs
This descriptive data brief includes prevalence-based summaries for birth defects listed in 
Table 1 from 38 of the 41 population-based birth defects surveillance programs contributing 
data to this report (three programs were excluded in the data brief due to their level of data 
aggregation). State programs were grouped by their case-finding approach (active or 
passive). The 15 programs in the active case-finding category were: Arizona, Arkansas, 
Delaware, Georgia (metropolitan Atlanta), Iowa, Louisiana, Massachusetts, Minnesota, New 
Hampshire, North Carolina, Oklahoma, Puerto Rico, South Carolina, Texas, and Utah; 23 
programs in the passive case-finding category were: Colorado, Florida, Illinois, Indiana, 
Kansas, Kentucky, Maine, Maryland, Michigan, Mississippi, Missouri, Nebraska, Nevada, 
New Jersey, New Mexico, New York, Oregon, Rhode Island, Tennessee, Vermont, Virginia, 
West Virginia, and Wisconsin.
The defects are displayed by organ system (Tables 2A: central nervous; 2B: ear and eye; 2C: 
cardiovascular; 2D: orofacial; 2E: gastrointestinal; 2F: genitourinary; 2G: musculoskeletal; 
and 2H: chromosomal). Within each organ system, the conditions are then presented, when 
possible, in order by the magnitude of the distribution of the prevalence estimates submitted 
from the 38 birth defects surveillance programs.
For each of the 47 defects, we present prevalence-based summary statistics by case-finding 
approach (total, active, passive) and by maternal race/ethnicity groups (white non-Hispanic, 
black non-Hispanic, Hispanic, and all race/ethnicity combined). Of note, for these analyses 
the state-specific data are not pooled across state programs. The mean prevalence is 
calculated as the mean of the individual state prevalences, with each state weighted equally, 
regardless of population size. We describe the range of state-specific prevalence estimates 
by presenting the mean, Chebyshev interval (mean ± two standard deviations) (Berenson et 
al., 2012), median (P50), inter-decile interval [10th percentile (P10), 90th percentile (P90)], 
and inter-quartile interval [25th percentile (P25), 75th percentile (P75)]. The mean and 
median describe the central tendency of the set of state-specific prevalence estimates, and 
the intervals describe the variation of the set of state-specific prevalence estimates. 
Specifically, the Chebyshev interval, a useful metric for non-normal distributions, captures 
Mai et al. Page 3
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
at least 75% of its state-specific prevalence estimates. Each inter-quartile interval captures 
approximately 50% of the state-specific prevalence estimates, and the inter-decile interval 
captures approximately 80% of the state-specific prevalence estimates. While the inter-
quartile interval is more familiar, the inter-decile interval is a better companion to the 
Chebyshev interval because they capture similar proportions of the state-specific prevalence 
estimates; thus both interval measures were included in the data tables. For example, 38 
state programs contributed data for anencephaly with a mean prevalence estimate of 1.7 
cases/10,000 live births (LB), with at least 75% of these 38 program prevalence estimates 
between 0.0 and 3.8 cases/10,000 LB (Chebyshev interval). The overall median is 1.5 cases/
10,000 LB, and approximately 80% of these 38 estimates are between 0.3 and 3.0 cases/
10,000 LB (inter-decile percentile interval). With respect to the inter-quartile percentile 
interval, approximately 50% of the 38 estimates are between 0.9 and 2.5 cases/10,000 LB.
The data tables include corresponding boxplots whose vertical widths are weighted to 
correspond to the race/ethnicity distribution of birth defects cases for non-Hispanic white, 
non-Hispanic black, and Hispanic (displayed from top to bottom, respectively). Figure 1 
details the components of the boxplots.
Additional data presentations are included for trisomies and gastroschisis by three maternal 
age categories (<25 years, 25–34 years, and 35 ± years) in Tables 3A and 3B, respectively. 
These tables use the same descriptive measures for central tendency and dispersion as the 
maternal race/ethnicity tables (i.e., mean, Chebyshev interval, median, inter-decile interval, 
and inter-quartile interval).
SELECTED HIGHLIGHTS OF BIRTH DEFECTS-SPECIFIC VARIABILITY
Central nervous system defects (Table 2A)—While the average (mean or median) 
prevalence estimates of anencephaly and spina bifida were highest among Hispanics across 
all programs, more variability was observed for this group compared with non-Hispanic 
whites and non-Hispanic blacks. For anencephaly, the Chebyshev interval for His-panics 
was 0.0 to 7.9 cases/10,000 LB while the interval was 0.0 to 3.5 cases/10,000 LB for non-
Hispanic whites and 0.0 to 4.1 cases/10,000 for non-Hispanic blacks. Anencephaly also 
exhibited higher overall prevalence and greater variability among programs with active case-
finding compared with passive case-finding. In contrast, the case-finding approach appeared 
to have little impact on both average prevalence and variability of spina bifida.
Passive case-finding programs generally had higher prevalence estimates than active case-
finding programs for holoprosencephaly, but the dispersion in these estimates was much 
wider (Chebyshev interval 0.0–6.6 cases/10,000 LB) for the passive compared with active 
case-finding programs (0.3–2.5 cases/10,000 LB).
Eye and ear defects (Table 2B)—The average prevalence and dispersion for the eye 
defects, anophthalmia/microphthalmia and congenital cataract, were relatively similar across 
the racial/ethnic groups (non-Hispanic whites, Hispanics, and non-Hispanic blacks). 
However, the active-case finding programs reported somewhat higher average prevalence 
estimates. Less dispersion in the prevalence estimates was observed for anophthalmia/
microphthalmia than for congenital cataract.
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The state prevalence estimates for anotia/microtia among Hispanics showed much more 
variability than other race/ethnicity groups (Chebyshev interval 0.0–8.4 cases/10,000 LB for 
Hispanics compared with 0.0–3.0 and 0.0–3.6 cases/10,000 LB for non-Hispanic whites and 
non-Hispanic blacks, respectively). While active case-finding programs reported 
approximately 50% higher prevalence estimates, this was accompanied by a wider 
dispersion around the mean and median values.
Cardiovascular defects (Table 2C)—The mean prevalence estimates reported were 
highest among non-Hispanic blacks for several cardiac conditions (interrupted aortic arch, 
atrioventricular septal defect [AVSD], tetralogy of Fallot); however, some of the higher 
observed differences were attenuated when examining the median values. For example, the 
prevalence estimate for interrupted aortic arch among non-Hispanic blacks shifted from a 
mean of 0.8 cases/10,000 LB to a median of 0.5 cases/10,000 LB, which was closer to the 
estimates for the other groups. Other birth defects (e.g., single ventricle, tricuspid valve 
atresia and stenosis, pulmonary valve atresia and stenosis) also seemed to have higher mean 
prevalence estimates among non-Hispanic blacks, but had wide overlapping inter-quartile 
ranges. Higher average prevalence among non-Hispanic whites was observed for aortic 
valve stenosis and coarctation of the aorta, and higher average prevalence among Hispanics 
for total anomalous pulmonary venous return.
Active case-finding programs reported relatively similar or higher average prevalence 
estimates for most cardiac conditions on the NBDPN birth defects list except for atrial septal 
defect. The average prevalence estimates for this condition were higher for passive case-
finding programs, and this was accompanied by wide dispersion. For example, the 
Chebyshev interval for atrial septal defect was 0.0 to 204.6 cases/10,000 LB for passive 
case-finding programs compared with 0.0 to 74.4 cases/10,000 LB. A similar pattern did not 
emerge for ventricular septal defect. For AVSD, active case-finding programs had 
substantially higher average prevalence across all three racial/ethnic groups than passive 
case-finding programs, with barely any overlap in the inter-quartile ranges. However, the 
dispersion was similar between active and passive programs.
Orofacial defects (Table 2D)—Little variation was observed in the average prevalence 
for choanal atresia across case-finding programs or racial/ethnic groups. Among clefts, non-
Hispanic blacks consistently showed the lowest average prevalence for all types of orofacial 
clefts (cleft lip alone, cleft lip with cleft palate, and cleft palate alone). The case-finding 
approach did not appear to impact the average prevalence of orofacial conditions or the 
spread of state prevalence values.
Gastrointestinal defects (Table 2E)—Even with relatively wide dispersions, the 
average prevalence estimates were similar among racial/ethnic groups except among non-
Hispanic blacks. Among this group, slightly higher average prevalence for biliary atresia 
and lower average prevalence for rectal and large intestinal atresia/stenosis, were noted.
While the prevalence estimates observed for the four gastrointestinal defects on the NBDPN 
list were similar across case-finding programs, the inter-quartile intervals from active case-
finding programs were narrower than those of passive case-finding programs.
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Genitourinary defects (Table 2F)—Compared with non-Hispanic whites and blacks, 
Hispanics had a higher prevalence of bladder exstrophy and renal agenesis/hypoplasia (in 
the active case-finding programs). However, the dispersion in the prevalence estimates was 
relatively wide. In fact, for the estimates for renal agenesis/hypoplasia among Hispanics, the 
Chebyshev interval was five times higher for active case-finding programs (0–36.3 cases/
10,000 LB) compared with passive case-finding programs (0–7.4 cases/10,000 LB). The 
average prevalence of congenital posterior urethral valves was higher among non-Hispanic 
blacks. Hispanics appeared to have a consistently lower prevalence of hypospadias.
The reported average prevalence for hypospadias and cloacal exstrophy were higher among 
states with passive case-finding ascertainment, but much of this was driven by a large 
dispersion. For example, the Chebyshev interval for cloacal exstrophy was 16 times wider 
for passive case-finding programs (0.0–8.3 cases/10,000 LB) compared with active case-
finding programs (0.0–0.5 cases/10,000 LB).
Musculoskeletal defects (Table 2G)—In general, average prevalence was similar 
across race/ethnic groups with the exception of omphalocele, which appeared to be higher 
among non-Hispanic blacks. Active case-finding programs reported higher average 
prevalence for clubfoot and omphalocele. For clubfoot, active case-finding programs not 
only reported higher prevalence estimates, but also less variability (mean of 16.7 cases/
10,000 LB and Chebyshev interval of 12.7–20.8 cases/10,000 LB) compared with passive 
case-finding programs (mean of 11.7 cases/10,000LB and Chebyshev interval of 1.6–21.7 
cases/10,000 LB).
As one of the new conditions added to the NBDPN list, craniosynostosis was reported by 
only 15 programs for this data brief. Active case-finding programs had much higher 
prevalence estimates across all three racial/ethnic groups, especially for non-Hispanic 
whites, with only a slight overlap in the inter-quartile ranges. The variations observed in the 
prevalence estimates appeared to be sensitive to extreme values (wide dispersion observed 
using the Chebyshev intervals but with tighter inter-quartile ranges).
Chromosomal conditions (Table 2H)—Hispanics seemed to have slightly higher 
average prevalence of trisomy 21; non-Hispanic blacks seemed to have slightly higher 
average prevalence of trisomies 13 and 18. The variability in the race-ethnicity specific 
estimates, however, is substantial, especially for trisomy 18, both between active and 
passive case-finding programs and within the group of states conducting active 
ascertainment. Active case-finding programs generally reported higher average prevalence 
for chromosomal conditions, but showed a wider inter-quartile dispersion except for deletion 
22 q11.2, where the range was extremely narrow (0.8–0.9 cases/10,000 LB).
Maternal age (Tables 3A and 3B)—The prevalence estimates for all three trisomy 
conditions were slightly higher among active case-finding programs, with a pronounced 
jump in prevalence estimates for older mothers (≥35 years), especially for Down syndrome. 
The variability in the prevalence estimates for trisomies 13 and 18 was markedly larger 
among the programs with active case-finding than programs with passive case-finding.
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For gastroschisis, the average prevalence estimates were highest among young mothers (<25 
years), with the overall magnitude of and variability in prevalence estimates relatively 
consistent across surveillance case-finding approaches.
Discussion
Population-based birth defects surveillance systems in the United States are generally 
established at the state level. The NBDPN has published state-specific birth defects counts 
and prevalence estimates for a range of major birth defects for almost two decades, but has 
increasingly focused its efforts on multi-state collaborative projects using pooled data to 
characterize the prevalence and public health burden, survival, and health outcomes of 
affected populations. The expanded utility of state-based birth defects data warrants a closer 
examination of the variability behind prevalence estimates for specific birth defects across 
programs. This report attempts to broadly describe variations observed in birth defects data 
across 38 population-based surveillance systems by examining two measures of central 
tendency (mean and median) and the accompanying dispersion measures (standard 
deviations around the mean values and inter-quartile and inter-decile intervals around 
median values). Much of the variability observed can likely be explained by (1) clinical 
practice and coding and (2) surveillance ascertainment methodology.
CLINICAL PRACTICE AND CODING
Population-based birth defects surveillance data are largely removed from direct medical 
care. Clinical practice and patient access to health care can affect how information is 
recorded in medical records. Prenatal care may be immediate, delayed, or absent which 
impacts the health of the pregnancy and whether (and when) a birth defect is identified and 
recorded. After delivery, differences in the level of hospital care, screening practices, and 
diagnostic capabilities among birthing facilities could affect which birth defects are detected 
and documented in medical records.
The quantity and quality of information ascertained from medical records and how 
diagnostic case information is coded can greatly affect the variations in prevalence estimates 
observed for several birth defects. For example, the wide dispersion observed in the average 
prevalence estimates for atrial septal defects among passive case-finding programs is likely 
driven by those programs’ reliance on administrative datasets to ascertain cases using an 
imprecise ICD-9-CM code that often times include other conditions, such as patent foramen 
ovale.
Other issues such as diagnostic certainty of conditions, and whether a program can 
definitively confirm cases, can affect observed variations. Salemi et al. (2012) compared the 
passive case ascertainment methodology used by the Florida Birth Defects Registry with an 
enhanced system that used hospital medical record review, and concluded that for 
epidemiologic or clinical studies, the program should implement a more comprehensive case 
ascertainment strategy that includes case confirmation.
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SURVEILLANCE ASCERTAINMENT METHODOLOGY
Surveillance ascertainment methodology, specifically how programs find cases, which 
pregnancy outcomes are included, and the type of data sources accessed, are critical drivers 
of variability of prevalence estimates. Hobbs et al. (2001) noted several potential sources of 
variability in case ascertainment methods, data sources, case inclusion criteria, inclusion of 
elective terminations and stillbirths, age limit, and diagnostic confirmation and precision.
The ability of birth defects surveillance programs to capture cases from all pregnancy 
outcomes is important, but capturing this data can be challenging. Whereas most systems 
capture both live births and fetal deaths, only approximately 40% are able to capture 
terminations of pregnancy (Mai et al., 2015). For some conditions, the lack of other 
pregnancy outcomes can greatly affect data completeness. Cragan and Gilboa (2009) found 
that adding prenatal sources from perinatologists’ offices to their data sources increased the 
total defect prevalence by approximately 7% (28 per 1000 to 30 per 1000). The increase was 
most pronounced for lethal conditions, such as anencephaly. In general, active case-finding 
programs report higher average prevalence estimates, but this is most likely driven by 
inclusion of all pregnancy outcomes.
Wide variations can be observed for rare events within a small population size. The 
occurrence of some individual types of birth defects can be considered rare, and when the 
counts are stratified further into subgroups, such as maternal race/ethnicity, some extreme 
variations are observed. For example, among active case-finding programs, the mean 
prevalence estimate for tetralogy of Fallot among Hispanics is almost twice the median 
prevalence estimate, due to extreme right skewness (Chebyshev interval 0.0–33.2 cases/
10,000 LB). This result is driven by one program that ascertained a few cases from a small 
Hispanic LB population (less than 1000 LB over a 5-year period).
Pooling data from multiple state programs for epidemiologic and etiologic studies assists in 
reducing certain extreme-values challenges. Examples of studies using pooled data include 
the NBDPN national estimates project and the National Birth Defects Prevention Study. The 
NBDPN developed national estimates using pooled data from programs that could confirm 
100% of the cases (Canfield et al., 2006; Parker et al., 2010). Likewise, the National Birth 
Defects Prevention Study, one of the largest case-control studies to examine risk factors for 
birth defects, used pooled birth defects data from 10 population-based birth defects 
surveillance programs that all followed a rigid study protocol for case inclusion (Reefhuis et 
al., 2015; Dolk, 2015).
CONCLUSIONS
Given a lack of a national system for population-based birth defects surveillance, multi-state 
data collaborations are important to address the public health impact of birth defects in the 
United States. As the utility of population-based birth defects surveillance data increases 
with applications for policy decisions, prevention efforts and the development of a research 
agenda, understanding the variability behind prevalence estimates for specific birth defects 
across states is key. True variation in occurrence is expected because populations have 
different underlying risks; however our organizational experience has shown that some 
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sources of variation are controllable. The NBDPN released national standards for data 
quality in 2014 that included performance measures around completeness, timeliness and 
accuracy of birth defects data (Anderka et al., in press). Implementation of those standards 
across surveillance systems will be an important step forward in controlling variability. 
Concerted efforts are needed to continue to improve birth defects surveillance across 
population-based programs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. 
Legend for the graphs in the data tables.
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TABLE 1
National Birth Defects Prevention Network (NBDPN) List of Reported Birth Defects by Disease 
Classification Codes
Birth defects
Disease classification codes
International 
Classification of Diseases, 
9th Revision, Clinical 
Modification (ICD-9-CM)
Centers for Disease Control and 
Prevention/British Pediatric 
Association Classification of Diseases 
(CDC/BPA)
Central nervous system
Anencephaly 740.0 – 740.1 740.00 – 740.10
Spina bifida without anencephaly 741.0, 741.9
without
740.0 – 740.1
741.00 – 741.99
without
740.00 – 740.10
Encephalocele 742.0 742.00 – 742.09
Holoprosencephaly 742.2 742.26
Eye
Anophthalmia/microphthalmia 743.0, 743.1 743.00 – 743.10
Congenital cataract 743.30 – 743.34 743.32
Ear
Anotia/microtia 744.01, 744.23 744.01, 744.21
Cardiovascular
Common truncus (truncus arteriosus) 745.0 745.00 (excluding 745.01)
Transposition of the great arteries (TGA) 745.10, .12, .19 745.10 – 745.12, 745.18 – 745.19
dextro-Transposition of great arteries (d-TGA) – for CCHD 
screeninga
745.10 745.10, 745.11,745.19
Tetralogy of Fallot 745.2 745.20 – 745.21, 747.31
Ventricular septal defect 745.4 745.40 – 745.49 (excluding 745.487, 
745.498)
Atrial septal defect 745.5 745.51 – 745.59
Atrioventricular septal defect (endocardial cushion defect) 745.60, .61, .69 745.60 – 745.69, 745.487
Pulmonary valve atresia and stenosis 746.01, 746.02 746.00, 746.01
Pulmonary valve atresia – or CCHD screeninga 746.01 746.00
Tricuspid valve atresia and stenosis 746.1 746.100, 746.106 (excluding 746.105)
Tricuspid valve atresia– for CCHD screeninga 746.1 746.100
Ebstein anomaly 746.2 746.20
Aortic valve stenosis 746.3 746.30
Hypoplastic left heart syndrome 746.7 746.70
Coarctation of aorta 747.10 747.10 – 747.19
Total anomalous pulmonary venous connection 747.41 747.42
Single ventricle 745.3 745.3
Interrupted aortic arch 747.11 747.215 – 747.217
Double outlet right ventricle 745.11 745.13 – 745.15
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Birth defects
Disease classification codes
International 
Classification of Diseases, 
9th Revision, Clinical 
Modification (ICD-9-CM)
Centers for Disease Control and 
Prevention/British Pediatric 
Association Classification of Diseases 
(CDC/BPA)
Orofacial
Cleft palate alone (without cleft lip) 749.0 749.00 – 749.09
Cleft lip alone (without cleft palate) 749.1 749.10 – 749.19
Cleft lip with cleft palate 749.20–749.25 749.20 – 749.29
Choanal atresia 748.0 748.00
Gastrointestinal
Esophageal atresia/tracheoesophageal fistula 750.3 750.30 – 750.35
Rectal and large intestinal atresia/stenosis 751.2 751.20 – 751.24
Biliary atresia 751.61 751.65
Small intestinal atresia/stenosis 751.1 751.10 – 751.19
Genitourinary
Renal agenesis/hypoplasia 753.0 753.00 – 753.01
Bladder exstrophy 753.5 753.50
Hypospadias 752.61 752.60 – 752.62 (excluding 752.61 and 
752.621)
Congenital posterior urethral valves 753.6 753.60
Cloacal exstrophy 751.5 751.555
Musculoskeletal
Gastroschisis 756.73 (as of 10/1/09) 756.71
Omphalocele 756.72 (as of 10/1/09) 756.70
Diaphragmatic hernia 756.6 756.610 – 756.617
Limb deficiencies (reduction defects) 755.2 – 755.4 755.20 – 755.49
Craniosynostosis No specific code 756.00 – 756.03
Clubfoot 754.51, 754.70 754.50, 754.73 (excluding 754.735)
Chromosomal
Trisomy 13 758.1 758.10 – 758.19
Trisomy 21 (Down syndrome) 758.0 758.00 – 758.09
Trisomy 18 758.2 758.20 – 758.29
Turner syndrome 758.6 758.60 – 758.69
Deletion 22q11.2 758.32 758.37
a
The primary targets for CCHD screening include seven conditions: hypoplastic left heart syndrome, pulmonary atresia with intact septum, 
tetralogy of Fallot, total anomalous pulmonary venous connection, dextro-transposition of great arteries (d-TGA), tricuspid atresia, and truncus 
arteriosus. The NBDPN traditionally monitors all TGA, and both atresia and stenosis for pulmonary and tricuspid valve conditions; however, for 
CCHD screening reporting purpose, these conditions are also reported as d-TGA, pulmonary valve atresia, and tricuspid valve atresia.
CCHD, critical congenital heart defect.
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TABLE 2A
Central Nervous System Defects Prevalence Estimates (Prevalence Per 10,000 Live Births): Measures of 
Central Tendency and Dispersion by Case-Finding Methodology and Maternal Race/ethnicity, 2008–2012.
**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th 
percentile; P75=75th percentile; P90=90tb percentile
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TABLE 2B
Eye and Ear Defects Prevalence Estimates (Prevalence Per 10,000 Live Births): Measures of Central 
Tendency and Dispersion by Case-Finding Methodology and Maternal Race/ethnicity, 2008–2012.
**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th 
percentile; P75=75th percentile; P90=90th percentile
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TABLE 2C
Cardiovascular Defects Prevalence Estimates (Prevalence Per 10,000 Live Births): Measures of Central 
Tendency and Dispersion by Case-Finding Methodology and Maternal Race/ethnicity, 2008–2012.
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**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th 
percentile; P7S=75th percentile; P90=90th percentile
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TABLE 2D
Orofacial Defects Prevalence Estimates (Prevalence per 10,000 Live Births): Measures of Central Tendency 
and Dispersion by Case-finding Methodology and Maternal Race/Ethnicity, 2008–2012.
**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th 
percentile; P75=75th percentile; P90=90th percentile
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TABLE 2E
Gastrointestinal Defects Prevalence Estimates (Prevalence per 10,000 Live Births): Measures of Central 
Tendency and Dispersion by Case-finding Methodology & Maternal Race/Ethnicity 2008–2012.
**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th 
percentiEe; P75=75th percentile; P90=90th percentile
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TABLE 2F
Genitourinary Defects Prevalence Estimates (Prevalence per 10,000 Live Births): Measures of Central 
Tendency and Dispersion by Case-finding Methodology and Maternal Race/Ethnicity 2008–2012.
*
Hypospadias prevalence per 10,000 male live births.
**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SO); P10=10th percentile; P25=25th 
percentile; P75=75th percentile; P9D=90th percentile
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Mai et al. Page 23
TABLE 2G
Musculoskeletal Defects Prevalence Estimates (Prevalence per 10,000 Live Births): Measures of Central 
Tendency and Dispersion by Case-finding Methodology and Maternal Race/Ethnicity, 2008–2012.
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**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebvshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th 
percentile; P75=75th percentile; P90=90th percentile
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TABLE 2H
Chromosomal Defects Prevalence Estimates (Prevalence per 10,000 Live Births): Measures of Central 
Tendency and Dispersion by Case-finding Methodology and Maternal Race/Ethnicity, 2008–2012
**
Total also includes Asian and Pacific Islander, American Indian/Alaska Native and other/unknown race/ethnicity.
NH=Non-Hispanic; n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th 
percentile; P75=75th percentile; P90=90th percentile
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TABLE 3A
Trisomy Prevalence Estimates (Prevalence Per 10,000 Live Births): Measures of Central Tendency and 
Dispersion by Case-Finding Methodology and Maternal Age, 2008–2012.
**
Total also includes unknown maternal age.
n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th percentile; P75=75th 
percentile; P90=90th percentile
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TABLE 3B
Gastrochisis Prevalence Estimates (Prevalence Per 10,000 Live Births): Measures of Central Tendency and 
Dispersion by Case-Finding Methodology and Maternal Age, 2008–2012.
**
Total also includes unknown maternal age.
n=number of state programs; Chebyshev interval=Mean ± 2 Standard Deviations (SD); P10=10th percentile; P25=25th percentile; P75=75th 
percentile; P90=90th percentile
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